ArticleJournal of nanobiotechnology2026
Therapeutic effects of mesenchymal stem cell-derived extracellular vesicles from different tissue sources on diminished ovarian reserve and the related mechanisms.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mesenchymal stem cells and derived extracellular vesicles in major respiratory diseases: from multifaceted molecular mechanisms to clinical perspectives.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundPatients with diminished ovarian reserve (DOR) significantly reduced success rates in assisted reproduction, making DOR a major clinical challenge in assisted reproductive technologies. Recent studies have indicated that extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) hold promise for improving ovarian function, yet the impact of tissue origin on EVs function remains unclear. Adipose tissue and the umbilical cord are common and easily accessible sources of MSCs. This study aimed to compare the therapeutic effects of adipose-derived MSC- EVs (A-EVs) and umbilical cord MSC- EVs (U-EVs) in a cyclophosphamide-induced DOR mouse model, investigate their underlying mechanisms and provide experimental evidence for selecting the most promising EVs source for clinical application.
resultsProteomic analysis revealed differences protein composition between U-EVs and A-EVs. Both A-EVs and U-EVs significantly increased serum AMH levels and improved fertility, whereas U-EVs produced more sustained reproductive benefits. Single-cell RNA sequencing and in vitro functional validation demonstrated that EV treatment reduced granulosa-cell apoptosis, oxidative stress, DNA-damage responses, and senescence signatures, with U-EVs exerting broader regulatory effects.
conclusionsIn conclusion, both A-EVs and U-EVs improved ovarian function in DOR mice; however, U-EVs demonstrated greater efficacy in promoting long-term fertility and inhibiting granulosa cell apoptosis, indicating greater potential for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.